Table 1.
Demographic and clinical characteristics of melanoma patients on immunotherapy
| Characteristic | All patients (n = 27) |
No progression (n = 15) |
Any progression (n = 12) | p a |
|---|---|---|---|---|
| Age (years)b, mean ± SD | 70.3 ± 11.9 | 66.6 ± 12.5 | 74.9 ± 9.6 | < 0.0001 |
| Male, % | 77.8 | 73.3 | 83.3 | 0.66 |
| White, % | 96.3 | 100 | 91.7 | 0.44 |
| BMI (kg/m2)b, mean ± SD | 27.5 ± 4.8 | 28.4 ± 4.3 | 26.5 ± 5.3 | < 0.0001 |
| Melanoma type, % | 0.02 | |||
| Nodular | 18.5 | 6.7 | 33.3 | |
| Acral lentiginous | 3.7 | 0 | 8.3 | |
| Superficial spreading | 3.7 | 0 | 8.3 | |
| Desmoplastic | 3.7 | 0 | 8.3 | |
| NOS/missing | 70.4 | 93.3 | 41.7 | |
| Driver mutation, % | 0.83 | |||
| NRAS | 18.5 | 13.3 | 25 | |
| BRAF | 25.9 | 33.3 | 16.7 | |
| None | 29.6 | 26.7 | 33.3 | |
| Missing | 25.9 | 26.7 | 25 | |
| Stageb, % | 0.68 | |||
| III | 33.3 | 40 | 25 | |
| IV | 66.7 | 60 | 75 | |
| LDH > 618 U/Lb, % | 7.4 | 0 | 16.7 | 0.22 |
| Sites of metastasisb,c, % | 0.21 | |||
| 0 | 40.7 | 53.3 | 25 | |
| 1–2 | 33.3 | 33.3 | 33.3 | |
| ≥ 3 | 25.9 | 13.3 | 41.7 | |
| Immunotherapy type, % | 0.44 | |||
| Anti-PD-1 | 51.9 | 46.7 | 58.3 | |
| Anti-CTLA-4 | 3.7 | 0 | 8.3 | |
| Anti-PD-1/anti-CTLA-4 | 44.4 | 53.3 | 33.3 | |
| Antibiotics in prior 6 months, % | 55.6 | 60 | 50 | 0.71 |
ap value for difference by progression status, from Wilcoxon rank-sum test for continuous variables or Fisher’s exact test for categorical variables
bCharacteristic prior to immunotherapy start (not at diagnosis)
cPatients with 0 sites of metastasis were resected with no evidence of disease and were being treated adjuvantly